BioNTech Ends Phase 2 Colorectal Cancer Trial After DSMB Flags Survival Imbalance
BNTX sits 40% above its 52-week low of $79.52.
Summary
BioNTech terminated its Phase 2 colorectal cancer trial for autogene cevumeran after a DSMB review found a survival imbalance between arms. The pancreatic cancer trial continues.
Updates
· Dow Jones Newswires — Shares fell 8.2% to $102.22 after the termination.
Key Events · Product Development and Regulatory · BNTX
-
Phase 2 CRC Trial Terminated
BioNTech and Genentech terminated BNT122-01 (NCT04486378) evaluating autogene cevumeran as adjuvant monotherapy in ctDNA-positive, surgically resected Stage II/III colorectal cancer.
-
DSMB Flags Survival Imbalance
The independent Data Safety Monitoring Board identified a numerical imbalance in overall survival between treatment arms and concluded further continuation was unlikely to change the efficacy outcome.
-
No New Safety Signals
The DSMB identified no new safety concerns regarding autogene cevumeran; the termination was based on efficacy, not safety.
-
Pancreatic Cancer Trial Unaffected
Phase 2 trial IMcode003 (NCT05968326) evaluating autogene cevumeran in combination with checkpoint inhibition and chemotherapy in adjuvant pancreatic ductal adenocarcinoma continues as planned.
Analysis · BNTX · Life Sciences
A Phase 2 trial of BioNTech's individualized mRNA cancer immunotherapy, autogene cevumeran, in colorectal cancer is being halted after an independent data monitoring board found a numerical imbalance in overall survival between treatment arms. The trial had already crossed a futility boundary in October 2025 but was allowed to continue pending more mature data. This termination removes a key oncology readout from BioNTech's pipeline at a time when the company is already under pressure from a wider-than-expected Q2 loss and a ~20% cut to 2026 revenue guidance. The company emphasizes that no new safety signals were identified and that a separate Phase 2 trial in pancreatic cancer continues, but the setback narrows the near-term evidence base for its mRNA cancer immunotherapy platform.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 977 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTX was trading at $111.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28B. The 52-week trading range was $79.52 to $124.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.